Shares of Catabasis Pharmaceuticals Inc. (CATB) were down over 31% in extended trading on Tuesday, following failure of its phase IIa clinical trial of CAT-2054 for the treatment of hypercholesterolemia.
Forex – financial instrument.Forex news
Shares of Catabasis Pharmaceuticals Inc. (CATB) were down over 31% in extended trading on Tuesday, following failure of its phase IIa clinical trial of CAT-2054 for the treatment of hypercholesterolemia.